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Antibody fragments facilitate crystallization of membrane proteins. 
We present our protocols to generate functional antibodies against membrane proteins. 
Crystal structure of a human GPCR in complex with Fab fragment has been obtained. 




Membrane proteins act as gateways to cells, and they are responsible for much of the 
communication between cells and their environments. Crystallography of membrane 
proteins is often limited by the difficulty of crystallization in detergent micelles. 
Co-crystallization with antibody fragments has been reported as a method to facilitate 
the crystallization of membrane proteins; however, it is widely known that the 
generation of mouse monoclonal antibodies that recognize the conformational epitopes 
of mammalian integral membrane proteins is typically difficult. Here, we present our 
protocols to generate functional mouse antibodies for the membrane protein 
crystallography, which have enabled us to solve crystal structures of mammalian 




Human cells have a wide variety of membrane proteins, which comprise 
approximately 30% of proteins encoded by the genome [1]. Many membrane proteins 
are located at cell surface; therefore, they are readily available to small molecule drugs 
circulating in the blood. Therefore, membrane proteins such as G-protein-coupled 
receptors (GPCRs), transporters, and channels are important targets for drug therapy, 
with approximately 70% of drugs currently available in the market known to target 
membrane proteins. In order to design new drugs and to understand their molecular 
mechanisms, it is essential to have information about their 3D structure, and this is 
usually obtained by X-ray crystallography. However, the number of determined and 
deposited membrane protein structures constitutes only approximately 0.5% of all 
deposited protein structures in the Protein Data Bank, owing to difficulties in the 
structural analyses of membrane proteins, with a major factor being the problems 
associated with their crystallization.  
Membrane proteins are localized within membranes; therefore, for purification 
purpose, they are solubilized using detergent. In this procedure, the detergent forms 
micelles covering the hydrophobic surface of the membrane protein, and the purified 
protein is generally crystallized as a complex with the detergent micelles. Detergent 
micelles are not small; micelles consisting of the variable detergent, n-dodecyl 
β-D-maltoside (frequently used in membrane protein crystallography) have a molecular 
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weight of approximately 65 kDa [2], which is higher than that of many integral 
membrane proteins. Thus, crystallization of a membrane protein–detergent micelle 
complex can be complicated by steric hindrance from the micelles, which can impede 
the protein-protein interactions that are desirable for crystallization. In this review, we 
describe a method for the crystallization of membrane proteins by using antibodies, and 
our protocols for the generation of functional antibodies to facilitate crystallization of 
membrane proteins including mammalian integral membrane proteins such as GPCRs 
and transporters.  
 
Co-crystallization with antibody fragments 
Fab and Fv fragments of mouse monoclonal antibodies have been shown to facilitate 
crystallization of several membrane proteins by increasing the polar surface area for 
protein-protein interactions within the crystal lattice [3-6] (Fig. 1). Iwata et al. were the 
first to succeed in solving the co-crystal structure of bacterial cytochrome c oxidase 
with antibody fragment (Fv) by using this strategy in 1995. Surprisingly, no direct 
interactions were found to exist between the membrane protein molecules, whereas Fv 
fragments were found to be involved in all crystal contacts [7]. Subsequently, various 
research groups successfully used this strategy to obtain structures of several important 
membrane proteins, including ion channels and membrane transporters (Table 1) 
[7-19,20,21,22-24]. Thus, crystallization using antibodies is a method that can be 
applied to any type of membrane protein.  
However, commercially available antibodies against membrane proteins seldom 
facilitate crystal formation. Most of these available antibodies are used for western 
blotting, and they recognize linear epitopes of membrane proteins because most of them 
have been raised against peptides or denatured protein. In this case, the fluctuations 
between the membrane protein and the bound antibody via a flexible linear epitope 
might be not conducive for a stable crystal lattice formation. In contrast, antibodies that 
bind to membrane proteins by recognizing their specific conformational epitopes are 
expected to facilitate crystallization with less fluctuation and through a larger 
hydrophilic region (Fig. 1). In fact, most antibodies known to facilitate the 
crystallization of membrane proteins recognize their conformational epitopes rather than 
a linear epitope. However, it is not simple to generate such an antibody for mammalian 
integral membrane proteins. Recently, Kobilka et al. have succeeded in raising camelid 
 4 
single-chain antibody fragments (nanobodies) that can recognize and stabilize the active 
state structure of human β2-adrenergic receptor, and they obtained the first active state 
crystal structure of the receptor in complex with the nanobody [22]. They also 
obtained the crystal structure of the receptor with a Fab fragment from a mouse 
monoclonal antibody; however, the structure, particularly on the extracellular side, was 
heavily disordered [5,21]. The problem may have been caused by fluctuations between 
the GPCR and the Fab fragment because the antibody recognized a flexible loop. We 
have modified the screening protocols to obtain mouse monoclonal antibodies that 
recognize the conformational epitopes of mammalian integral membrane proteins, and 
these methods are summarized below. 
 
Protocols of mouse antibody generation 
Liposome immunization---In conventional immunization methods for the preparation 
of antibodies against membrane proteins, partial oligopeptides or purified samples 
solubilized with detergent are used to immunize mice; however, obtaining antibodies 
that recognize the conformational epitopes is difficult using these methods. Antibodies 
that bind to a part of the oligopeptides can be obtained using partial oligopeptide 
immunization, and the majority of antibodies obtained using purified sample 
immunization recognize denatured structures because blood dilutes the detergent, 
resulting in immediate denaturation of the purified membrane protein. To avoid this 
difficulty, we use a reconstituted liposome for immunization (“liposome 
immunization”); the target membrane protein is reconstructed without denaturation in 
phospholipid vesicles consisted of hen egg phosphatidyl choline with the adjuvant Lipid 
A, a lipid component derived from gram-negative bacteria, which acts on Toll-like 
receptor 4 to enhance innate immune activity as described elsewhere [5] (Fig. 2a). Use 
of immunodeficient mice (MRL/lpr) allowed efficient preparation of monoclonal 
antibodies against mammalian membrane proteins, without occurrence of 
immunotolerance. Adoption of this method led to a greater than 10-fold elevation of 
antibody titers compared to immunization of normal mice (BALB/c) with a detergent 
solubilized receptor.   
First screening: liposome ELISA---Besides immunization and screening methods, 
procedures were conducted according to the method developed by Milstein et al. for the 
preparation of mouse monoclonal antibodies [25]. After the antibody titer increased, the 
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mouse spleen was excised, and myeloma cells were fused with antibody-producing B 
cells by using polyethylene glycol (PEG) to prepare hybridomas by HAT selection. 
Enzyme linked immunosorbent assay (ELISA) is frequently used as the first screening 
assay for antibodies. In general, antigens are fixed on a plastic plate to detect antibodies 
that recognize them; however, using purified membrane proteins as antigens caused 
problems with the use of ELISAs, in that either the presence of detergent resulted in few 
antigens being fixed to the plastic plate, or repeated washings denatured the membrane 
protein. Thus, we seldom obtained useful antibodies that recognize conformational 
epitopes by using this method. Therefore, we developed a method, “liposome ELISA” 
by using purified samples reconstituted into liposomes containing biotinylated lipids 
(biotinyl phosphatidylethanolamine) to maintain the protein in its native conformation 
and effectively immobilize liposomes onto streptavidin-coated plates as described in 
international patent WO 2010/126115 (Fig. 2b). Although we were concerned that the 
use of liposomes for immunization may result in antibodies against lipids, in practice 
only approximately 10%–20% of the antibodies obtained recognized lipids, and this was 
regarded as an acceptable level. 
Second screening: denatured dot blot---The first ELISA screening, described above, 
selected antibodies recognizing the native structure of the target membrane protein. To 
eliminate antibodies that recognize a liner epitope, N and C termini or unstructured 
regions in the native structure, we performed a dot blot (“denatured dot blot”) by using 
purified samples denatured with 1% sodium dodecyl sulfate (Fig. 2c). Thus, we selected 
antibodies that did not bind to the denatured protein, suggesting that they recognize the 
conformational epitopes present only in the native form of the protein. In practice, 
approximately 10%–20% of the antibodies were positive by the liposome-ELISA assay 
and negative by the denatured dot blot technique, which were selected. 
Third screening: binding affinity selection by Biacore---Although antibodies 
recognizing conformational epitopes are obtained by the methods described above, if 
they have weak binding affinities and can dissociate immediately, they are not suitable 
for co-crystallization. Thus, it is important to screen for antibodies with high binding 
affinities. We constructed an evaluation system by using a Biacore T100 analyzer that 
works on the principle of surface plasmon resonance (Fig. 2d). Monoclonal anti-mouse 
Fc fragment antibody is immobilized on a sensor chip (CM5) and antibodies in 
hybridoma culture supernatants are tightly trapped by the Fc antibody fixed on the 
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sensor chip. Purified sample in detergent is then passed over the surface, and the 
specific binding is monitored to screen for those with dissociation constants (KD) below 
10 nM. In this experiment, almost half of the selected antibodies that passed the first 
and second screenings also met this criterion. This method allows testing of 
approximately 100 different culture supernatants in half a day by using the same chip. 
 
The combination of these immunization-screening techniques enabled us to obtain 
high affinity antibodies that recognize conformational epitopes against various 
membrane proteins, including GPCRs, membrane transporters, and ion channels from 
various species—spanning humans to bacteria. Further, we succeeded in obtaining the 
crystal structure of a human GPCR in complex with the selected antibody fragments as 
described below. 
 
Generation of functional antibodies for a human GPCR 
Human A2A adenosine receptor (A2AAR) is an important GPCR involved in the 
control of various physiological activities, including regulation of glutamine and 
dopamine release in the brain [26]. Specific inhibitors of the receptor are in advanced 
clinical trials for the treatment of Parkinson’s disease [27]. Several crystal structures of 
stabilized A2AAR mutants (T4 lysozyme [or b562RIL]-fusion mutants in intercellular 
loop 3 [ICL3] and alanine-scanning mutants) have been obtained by breakthroughs in 
protein engineering and crystallography over the past 5 years [28,29,30,31,32]. We 
purified A2AAR with a complete ICL3 [33] and raised mouse monoclonal antibodies 
against it by using the conventional mouse hybridoma system combined with improved 
screening methods as described above. We obtained 24 monoclonal antibodies that 
bound to native A2AAR with high affinity (KD < 10 nM) but did not recognize the 
denatured receptor [24]. Eight of the antibodies variably inhibited agonist binding to 
the purified receptor, and one (IgG2838) completely inhibited agonist binding but did 
not affect antagonist binding. In addition, these functional antibodies also drastically 
improved the thermostability of A2AAR, indicating that they are likely to be effective 
for co-crystallization. 
 
Crystal structure of the GPCR-Fab complex 
The Fab fragment was generated from the functional antibody (IgG2838, which 
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completely inhibited agonist binding) by papain cleavage. The A2AAR-Fab complex 
was purified by size-exclusion chromatography and crystallized in detergent. We 
obtained the crystal structures of the complex with antagonist (ZM241385) at 2.7 Å 
[24]. The Fab fragment recognized the intracellular side of the receptor (Fig. 3a), and 
its complementarity-determining region, CDR-H3, was unusually extended and 
penetrated into an internal cavity formed by an α-helical bundle of the receptor, which 
interacted with helices II, III, VI, and VIII by forming 7 hydrogen bonds (Fig. 3b). 
Furthermore, other CDRs also interacted with helices I, II, III, VI, VIII, and ICL3 
through 11 hydrogen bonds. Thus, the Fab fragment recognized the wide intracellular 
surface of A2AAR with high affinity. Despite the fact that the antibody bound to the 
intracellular side of the receptor, it blocked the binding of the agonist on the 
extracellular side but did not affect the binding of the antagonist, as described above. 
These findings indicate that the receptor is locked into an inactive conformation by tight 
binding of the functional antibody and that the conformation of the intracellular side and 
the ligand binding on the extracellular side are strongly coupled.  
 
Conclusion 
We succeeded in obtaining several antibodies to facilitate the crystallization of other 
mammalian integral membrane proteins such as membrane transporters by using this 
strategy (unpublished data). In the most trials, we were also able to obtain functional 
antibodies that modulate the activity of the target. This is probably because the antibody 
binds to the protein by recognizing several conformational epitopes in the native 
structure, thus stabilizing a particular conformation and/or preventing the 
conformational changes of the target protein, as in the case of the A2AAR. 
Co-crystallization using these functional antibodies might enable us to determine the 
transitional 3D structures that are usually very difficult to capture. We expect that our 
technique could be used to determine the crystal structures of different snapshots of 
targeted membrane proteins to increase understanding of molecular mechanisms and 
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Figure 1. Schematic illustration of co-crystallization of integral membrane protein with 
antibody fragment. Fab fragment of mouse monoclonal antibody facilitates 
crystallization of the membrane protein by increasing the polar sruface area. 
 
Figure 2. Graphical protocols to obtain mouse monoclonal antibodies that facilitate the 
crystallization of mammalian integral membrane proteins.  See text for details. 
 
Figure 3. Structure of the A2AAR-Fab complex. a, Overall structure viewed parallel to 
the membrane. A2AAR and the Fab light and heavy chains are shown in 
blue-gray, green and yellow, respectively. The bound antagonist ZM241385 in 
the ligand-binding pocket is shown as a space-filling model. b, Transparent 
surface representation of the interface between A2AAR (top) and Fab fragment 
(bottom). Relative to a, A2AAR has been rotated 90o around a horizontal axis, 
whereas Fab fragment is shown in the same orientation. Surface within 4 Å of 
CDR-H3 are colored red. 
Table 1. List of co-crystal structures of membrane protein with antibody fragment. 
Membrane Protein PDB code ligand format Resolution Source TM helices Reference 
Enzymes 
Cytochrome c oxidase 
Cytochrome bc1 complex 
Nitric oxide reductase 






KcsA K+ channel, channel domain 
KcsA K+ channel, full length 
ClC H+/Cl- antiporter 
KvAP voltage-gated K+ channel, full length 
KvAP voltage-gated K+ channel, full length 
KvAP voltage-gated K+ channel, sensor domain 
GluCl glutamate-gated Cl- channel 
 
Transporter 
AdiC Arg/Agmatine antiporter 
ApcT Amino acid transporter 
LeuT Leucine transporter (outward open) 
LeuT Leucine transporter (inward open) 
 
G protein coupled receptor 
β2 adrenergic receptor, antagonist bound 
β2 adrenergic receptor, agonist bound 
β2 adrenergic receptor, Gs complex 
A2A adenosine receptor, antagonist bound 
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